Iradimed (IRMD) EBITDA Margin (2013 - 2026)
Iradimed's (IRMD) quarterly EBITDA Margin came in at 32.93% in Q1 2026, up 509.0% year-on-year from 5.41% in Q1 2025, and up 5.33% on a QoQ basis from 31.26% in Q4 2025.
Iradimed (IRMD) EBITDA Margin (2013 - 2026) Analysis & Trends
Iradimed (IRMD) has 14 years of EBITDA Margin data on file, last reported at 32.93% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 509.0% year-over-year to 32.93% in Q1 2026; TTM through Mar 2026 was 32.4%, a 226.0% increase from a year earlier, with the FY2025 full-year figure at 31.2%, up 121.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 32.93%, up from 31.26% in the prior quarter.
- Over the last five years, EBITDA Margin for IRMD reached as high as 35.78% in Q3 2023 and fell as low as 24.98% in Q1 2022.
- Historically, EBITDA Margin has averaged 30.39% across 5 years, with a median of 30.82% in 2022.
- Across the five-year window, EBITDA Margin jumped 1395 bps in 2022 and tumbled 419 bps in 2024, its largest moves.
- Year by year, EBITDA Margin stood at 28.62% in 2022, then advanced by 3 bps to 29.57% in 2023, then gained by 1 bps to 29.92% in 2024, then grew by 4 bps to 31.26% in 2025, then rose by 5 bps to 32.93% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 32.93% in Q1 2026, 31.26% in Q4 2025, and 32.23% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Iradimed | 1.20 Bn | 1.14 Bn | 16.81 Mn | 32.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.93% |
| Dec 31, 2025 | 31.26% |
| Sep 30, 2025 | 32.23% |
| Jun 30, 2025 | 33.26% |
| Mar 31, 2025 | 27.84% |
| Dec 31, 2024 | 29.92% |
| Sep 30, 2024 | 31.59% |
| Jun 30, 2024 | 31.39% |
| Mar 31, 2024 | 26.98% |
| Dec 31, 2023 | 29.57% |
| Sep 30, 2023 | 35.78% |
| Jun 30, 2023 | 30.77% |
| Mar 31, 2023 | 25.89% |
| Dec 31, 2022 | 28.62% |
| Sep 30, 2022 | 30.82% |
| Jun 30, 2022 | 32.75% |
| Mar 31, 2022 | 24.98% |
| Dec 31, 2021 | 26.19% |
| Sep 30, 2021 | 28.30% |
| Jun 30, 2021 | 18.80% |